US04016X1019
© Globe Newswire
15.12.2025
ARGX
LISTED
NASDAQ
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
News Preview
15 December, 2025, 7:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2025
ARGX
LISTED
NASDAQ
argenx Announces Results of Extraordinary General Meeting of Shareholders
News Preview
November 18, 2025 – 10:01 PM CET...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ARGX
LISTED
NASDAQ
/C O R R E C T I O N from source -- argenx Canada Inc./
News Preview
In the news release, argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada, issued 05-Nov-2025 by argenx Canada Inc. over CNW, we are advised by the company that the quote in the third paragraph has been revised. The complete, corre...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
30.10.2025
ARGX
LISTED
NASDAQ
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
$1.13 billion in third quarter global product net sales ...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
29.10.2025
ARGX
LISTED
NASDAQ
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
News Preview
October 29, 2025, 8:00 AM PT...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2025
ARGX
LISTED
NASDAQ
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
News Preview
October 15, 2025, 7:00 AM CEST...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ARGX
LISTED
NASDAQ
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
News Preview
October 3, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2025
ARGX
LISTED
NASDAQ
argenx to Present at Upcoming Investor Conferences
News Preview
August 28, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September:...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ARGX
LISTED
NASDAQ
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
News Preview
August 25, 2025, 7:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.08.2025
ARGX
LISTED
NASDAQ
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
News Preview
August 19, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight | Pioneering MuSK Biology with ARGX-119” on Tuesday, September 16, 2025, at 2:00pm ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.07.2025
ARGX
LISTED
NASDAQ
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
News Preview
July 24, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 20...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
ARGX
LISTED
NASDAQ
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
News Preview
...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
20.06.2025
ARGX
LISTED
NASDAQ
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
News Preview
June 20, 2025, 7:00 PM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2025
ARGX
LISTED
NASDAQ
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
News Preview
June 11, 2025, 12:01 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
ARGX
LISTED
NASDAQ
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
News Preview
June 3, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl Gubitz, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2025
ARGX
LISTED
NASDAQ
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
$790 million in first quarter global product net sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2025
ARGX
LISTED
NASDAQ
argenx to Present at BofA Securities 2025 Health Care Conference
News Preview
May 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, and members of the management team will present at the BofA Securities 2025 Health Care Co...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2025
ARGX
LISTED
NASDAQ
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
News Preview
May 1, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 20...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.04.2025
ARGX
LISTED
NASDAQ
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
News Preview
April 28, 2025, 07:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.04.2025
ARGX
LISTED
NASDAQ
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
News Preview
April 11, 2025, 10:01 PM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.04.2025
ARGX
LISTED
NASDAQ
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
News Preview
April 10, 2025, 11:45 PM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.04.2025
ARGX
LISTED
NASDAQ
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
News Preview
April 8, 2025, 7:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.03.2025
ARGX
LISTED
NASDAQ
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
News Preview
Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced clinical trial and real-world data for VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvf...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
ARGX
LISTED
NASDAQ
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
News Preview
$737 million in fourth quarter and $2.2 billion in full year global product net sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
ARGX
LISTED
NASDAQ
argenx to Present at TD Cowen 45th Annual Healthcare Conference
News Preview
February 25, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.02.2025
ARGX
LISTED
NASDAQ
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
News Preview
February 20, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full yea...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
ARGX
LISTED
NASDAQ
argenx Highlights 2025 Strategic Priorities
News Preview
Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
ARGX
LISTED
NASDAQ
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 1...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.12.2024
ARGX
LISTED
NASDAQ
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
News Preview
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2024
ARGX
LISTED
NASDAQ
argenx to Present at Upcoming Investor Conferences
News Preview
November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2024
ARGX
LISTED
NASDAQ
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
News Preview
November 20, 2024, 7:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
ARGX
LISTED
NASDAQ
argenx to Participate at Upcoming Investor Conferences
News Preview
November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in November:...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2024
ARGX
LISTED
NASDAQ
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
News Preview
$573 million in third quarter global net product sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2024
ARGX
LISTED
NASDAQ
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
News Preview
October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quar...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2024
ARGX
LISTED
NASDAQ
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
News Preview
Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2024
ARGX
LISTED
NASDAQ
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
News Preview
ADHERE was largest and most innovative clinical trial of CIDP patients to date...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2024
ARGX
LISTED
NASDAQ
argenx to Present at Upcoming Investor Conferences
News Preview
August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September:...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2024
ARGX
LISTED
NASDAQ
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
News Preview
$478 million in second quarter global net product sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2024
ARGX
LISTED
NASDAQ
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
News Preview
July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 25, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its half year 2024 f...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2024
ARGX
LISTED
NASDAQ
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
News Preview
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
ARGX
LISTED
NASDAQ
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
News Preview
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.06.2024
ARGX
LISTED
NASDAQ
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
News Preview
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP)...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2024
ARGX
LISTED
NASDAQ
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
News Preview
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2024
ARGX
LISTED
NASDAQ
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
News Preview
June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
ARGX
LISTED
NASDAQ
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
News Preview
$398 million in first quarter global net product sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2024
ARGX
LISTED
NASDAQ
argenx to Present at BofA Securities 2024 Health Care Conference
News Preview
May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14,...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2024
ARGX
LISTED
NASDAQ
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
News Preview
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 f...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
